Article
Immunology
Yaping Chen, Hao Huang, Yuan Li, Wenlu Xiao, Yingting Liu, Rongzhang Chen, Yulan Zhu, Xiao Zheng, Changping Wu, Lujun Chen
Summary: Combination immunotherapy based on immune checkpoint inhibitors (ICIs) has shown great success in cancer treatment, and the combination of ablation and immunotherapy has potential for the treatment of liver metastasis of colorectal cancer (CRC). The expression of TIGIT was up-regulated after microwave ablation (MWA), and the combination of MWA and TIGIT blockade significantly promoted the expansion and functions of CD8(+) tumor-infiltrating lymphocytes (TILs) and reshaped myeloid cells in the tumor microenvironment (TME).
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Alex Frias, Luca Di Leo, Asier Antoranz, Loulieta Nazerai, Marco Carretta, Valerie Bodemeyer, Chiara Pagliuca, Christina Dahl, Giuseppina Claps, Giulio Eugenio Mandelli, Madhavi Dipak Andhari, Maria Pires Pacheco, Thomas Sauter, Caroline Robert, Per Guldberg, Daniel Hargbol Madsen, Francesco Cecconi, Francesca Maria Bosisio, Daniela De Zio
Summary: Loss of Ambra1 in melanoma affects the tumor immune microenvironment (TIME) and the antitumor immune response. It leads to changes in TIME composition and reduces the infiltration of regulatory T cells, resulting in accelerated tumor growth and decreased overall survival. However, loss of Ambra1 also sensitizes melanoma to anti-PD-1 treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Chemistry, Multidisciplinary
Ting Yu, Wen Nie, Zehua Hong, Yihong He, Jing Chen, Xue Mi, Shuping Yang, Xiaoling Li, Bilan Wang, Yunzhu Lin, Xiang Gao
Summary: By utilizing the RGD-DMA/pCCL19-BMS-1 system, significant inhibition of tumor progression was achieved, along with induction of locally high concentrations of immunostimulatory cytokines at tumor sites, effectively reshaping the immunosuppressive TME.
ADVANCED FUNCTIONAL MATERIALS
(2021)
Review
Oncology
Adria Archilla-Ortega, Carla Domuro, Juan Martin-Liberal, Purificacion Munoz
Summary: Immunotherapy is a promising strategy for enhancing antitumoral immunity. However, many patients do not respond to current immunotherapy. An integrative understanding of tumor-immune infiltrate and immune cell IC expression and function is crucial for designing effective therapies. Simultaneous blockade of newly identified ICs, as well as previously described ICs, could improve antitumor response.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Camille Moeckel, Katrina Bakhl, Ilias Georgakopoulos-Soares, Apostolos Zaravinos
Summary: Cancer is a leading cause of death worldwide, and research on potential therapeutics, including immune checkpoint inhibitors (ICIs), has been extensive. Initially, programmed-death ligand-1 was used as a biomarker to predict the effectiveness of ICIs. However, the heterogeneous expression of this biomarker in the tumor microenvironment led to the exploration of tumor mutation burden (TMB).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Lara Heij, Jan Bednarsch, Xiuxiang Tan, Mika Rosin, Simone Appinger, Konrad Reichel, Dana Pecina, Michail Doukas, Ronald M. van Dam, Juan Garcia Vallejo, Florian Ulmer, Sven Lang, Tom Luedde, Flavio G. Rocha, Shivan Sivakumar, Ulf Peter Neumann
Summary: Background: The tumor microenvironment (TME) in cholangiocarcinoma (CCA) influences the immune environment, but reliable biomarkers to predict treatment response are lacking. This study assessed the levels of checkpoint molecules, macrophages, and T cells in 50 intrahepatic CCA cases. Results showed that high densities of PD-L1 were more abundant in the sclerotic tumor region. Lymph node metastasis correlated with CD4_ICOS_TIGIT co-expression and CD8_PD-L2 expression, indicating a poor prognosis for patients with these checkpoint expression profiles. Multiple co-expressions occurred, suggesting the potential for combination therapy.
Article
Cell Biology
Guangdi Chu, Wenhong Shan, Xiaoyu Ji, Yonghua Wang, Haitao Niu
Summary: The study identified three tumor microenvironment patterns in urothelial cancer and developed a TMSig to predict patient prognosis and response to immunotherapy effectively. Targeted macrophage treatment shows great potential for individualized precision therapy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Cell Biology
Cor J. Ravensbergen, Meaghan Polack, Jessica Roelands, Stijn Crobach, Hein Putter, Hans Gelderblom, Rob A. E. M. Tollenaar, Wilma E. Mesker
Summary: The study predicted the responsiveness of colon adenocarcinoma tumors to ICI therapy using bioinformatics approaches. Tumors with high stromal content showed increased T regulatory cell infiltration but did not predict response to ICI therapy.
Article
Oncology
Gaigai Wei, Huiling Zhang, Haiping Zhao, Jing Wang, Nana Wu, Leying Li, Jiaying Wu, Duanwu Zhang
Summary: Immune checkpoints in the tumor microenvironment are crucial for modulating anti-tumor immunity, and immune checkpoint inhibitors have transformed cancer therapy. However, current immunotherapies face challenges such as unresponsiveness and limited efficacy, highlighting the importance of exploring new mechanisms and targets for cancer treatment.
Review
Immunology
Mohammad Hossein Kazemi, Alireza Najafi, Jafar Karami, Foad Ghazizadeh, Hassan Yousefi, Reza Falak, Elahe Safari
Summary: Recent advancements in cancer immunotherapy, particularly immune checkpoint (IC) blockers, have shown promising results in clinical settings. Immunometabolism plays a crucial role in regulating immune responses, and dual targeting of ICs and metabolic pathways may help restore immune cells' antitumor activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Zihao Yan, Siwen Chu, Chen Zhu, Yunhe Han, Qingyu Liang, Shuai Shen, Wen Cheng, Anhua Wu
Summary: This study established a T-cell activation-related risk score based on mRNA expression profiles to evaluate the prognosis and immunotherapy response of GBM patients. The high-risk group had poorer prognosis, stronger immune response, and a more complex tumor immune microenvironment. The immunotherapy score obtained by combining the risk and priming scores was found to be a good evaluation index for ICB response in GBM patients, providing potential treatment opportunities.
Review
Biochemistry & Molecular Biology
Ruiwen Ruan, Li Li, Xuan Li, Chunye Huang, Zhanmin Zhang, Hongguang Zhong, Shaocheng Zeng, Qianqian Shi, Yang Xia, Qinru Zeng, Qin Wen, Jingyi Chen, Xiaofeng Dai, Jianping Xiong, Xiaojun Xiang, Wan Lei, Jun Deng
Summary: FGF/FGFR signaling is important in cell fate and angiogenesis, and its dysregulation can drive tumorigenesis. Combining FGFR inhibitors with immune checkpoint blockade may be a promising treatment option for patients with dysregulated FGF/FGFR signaling.
Article
Immunology
Yonghua Cai, Ke Li, Jie Lin, Xianqiu Liang, Wei Xu, Zhengming Zhan, Shuaishuai Xue, Yu Zeng, Peng Chai, Yangqi Mao, Zibin Song, Lei Han, Ye Song, Xian Zhang, Hai Wang
Summary: This study explores the role of pyroptosis in glioma and identifies three pyroptosis subtypes with different prognoses. It also finds that patients with high gasdermin-related prognostic index (GPI) are more sensitive to certain treatments. Gasdermin D is identified as a potential biomarker in pyroptosis-inducible therapy combined with immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Materials Science, Multidisciplinary
Xin Li, Yu Zhen, Shanshan Li
Summary: This article reviews the significance of immune checkpoint blockade, photodynamic therapy, and nanotechnology in cancer treatment, highlighting the promising results of their combination in preclinical models and potential clinical applications.
MATERIALS & DESIGN
(2021)
Article
Immunology
Zihan Zhao, Siyang Liu, Rui Sun, Wenjie Zhu, Yulin Zhang, Tianyao Liu, Tianhang Li, Ning Jiang, Hongqian Guo, Rong Yang
Summary: Bladder cancer is a highly malignant tumor with limited improvement in prognosis and survival rates. Immune checkpoint inhibitors have revolutionized the treatment of bladder cancer, but their clinical application is limited by low response rates. This study investigated the combination of oxaliplatin and anti-PD-1 inhibitor in bladder cancer mouse models and found that this combination therapy was more efficient than medication alone.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Daniel Pietrasz, Shufang Wang-Renault, Julien Taieb, Laetitia Dahan, Mathilde Postel, Jerome Durand-Labrunie, Karine Le Malicot, Claire Mulot, Yves Rinaldi, Jean-Marc Phelip, Solene Doat, Helene Blons, Aurelien de Reynies, Jean-Baptiste Bachet, Valerie Taly, Pierre Laurent-Puig
Summary: In this study, ctDNA was detectable in 56.8% of patients with mPDAC and confirmed as an independent prognostic marker based on a large series derived from clinical trials.
BRITISH JOURNAL OF CANCER
(2022)
Review
Oncology
Wolf H. Fridman, Maxime Meylan, Florent Petitprez, Cheng-Ming Sun, Antoine Italiano, Catherine Sautes-Fridman
Summary: B cells play a critical role in the tumor microenvironment, particularly within tertiary lymphoid structures (TLS). The presence of mature TLS, high density of B cells and plasma cells, and antibodies targeting tumor-associated antigens are associated with favorable clinical outcomes and response to immunotherapy. However, polyclonal B cell activation can lead to pro-inflammatory responses. Novel therapeutic approaches are being explored to enhance the development of TLS and anti-tumor B cells for cancer therapy.
NATURE REVIEWS CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
C. Gallois, M. Sroussi, S. Mouillet-Richard, C. Mulot, L. M. Dourthe, T. Mazard, M. Jary, C. de la Fouchardiere, C. Lecaille, W. Lahlou, J. Tabernero, J-L. van Laethem, C. Lepage, J. F. Emile, J. Taieb, A. de Reynies, P. Laurent-Puig
ANNALS OF ONCOLOGY
(2022)
Meeting Abstract
Oncology
C. D. S. Groeneveld, V. Harter, S. Culine, C. Krucker, V. Dixon, A. De Reynies, C. Pfister, F. Radvanyi, Y. Allory
ANNALS OF ONCOLOGY
(2022)
Article
Urology & Nephrology
Ming-Jun Shi, Jacqueline Fontugne, Aura Moreno-Vega, Xiang-Yu Meng, Clarice Groeneveld, Florent Dufour, Aurelie Kamoun, Sia Viborg Lindskrog, Luc Cabel, Clementine Krucker, Audrey Rapinat, Claire Dunois-Larde, May-Linda Lepage, Elodie Chapeaublanc, Olivier Levrel, Victoria Dixon, Thierry Lebret, Anna Almeida, Aurelien De Reynies, Natacha Rochel, Lars Dyrskjot, Yves Allory, Francois Radvanyi, Isabelle Bernard-Pierrot
Summary: FGFR3 mutations are associated with male sex bias in bladder cancer. Through studies on a transgenic mouse model, it has been found that FGFR3 mutations can initiate bladder cancer and potentially impact male sex bias through FGFR3-dependent downregulation of estrogen receptor.
Article
Oncology
I. Hernandez-Verdin, E. Kirasic, K. Wienand, K. Mokhtari, S. Eimer, H. Loiseau, A. Rousseau, J. Paillassa, G. Ahle, F. Lerintiu, E. Uro-Coste, L. Oberic, D. Figarella-Branger, O. Chinot, G. Gauchotte, L. Taillandier, J. -P. Marolleau, M. Polivka, C. Adam, R. Ursu, A. Schmitt, N. Barillot, L. Nichelli, F. Lozano-Sanchez, M. -J. Ibanez-Julia, M. Peyre, B. Mathon, Y. Abada, F. Charlotte, F. Davi, C. Stewart, A. de Reynies, S. Choquet, C. Soussain, C. Houillier, B. Chapuy, K. Hoang-Xuan, A. Alenorn
Summary: Through comprehensive multi-omic analysis, we identified and characterized four molecular patterns in PCNSL, which have a distinct prognostic impact and can guide future clinical stratification and targeted interventions.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Xiaofan Lu, Yann Vano, Alexandra Helleux, Xiaoping Su, Veronique Lindner, Guillaume Davidson, Roger Mouawad, Jean-Philippe Spano, Morgan Roupre, Reza Elaidi, Eva Comperat, Virginie Verkarre, Chengming Sun, Christine Chevreau, Mostefa Bennamoun, Herve Lang, Thibault Tricard, Wenxuan Cheng, Li Xu, Irwin Davidson, Fangrong Yan, Wolf Herman Fridman, Catherine Sautes-Fridman, Stephane Oudard, Gabriel G. Malouf
Summary: This study identified a novel epigenetic phenotype associated with resistance to immune checkpoint inhibitors (ICIs) in clear-cell renal cell carcinomas (ccRCC). This phenotype, called TED, was found to be associated with sarcomatoid differentiation, poor clinical outcome and resistance to first-line ipilimumab-nivolumab combination therapy. TED exhibited specific epigenetic alterations, gene expression signatures and tumor microenvironment characteristics.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Constance Thibault, Aude Flechon, Laurence Albiges, Charlotte Joly, Philippe Barthelemy, Marine Gross-Goupil, Christine Chevreau, Elodie Coquan, Frederic Rolland, Brigitte Laguerre, Gwenaelle Gravis, Nicolas Pecuchet, Reza-Thierry Elaidi, Marc-Olivier Timsit, Meryem Brihoum, Edouard Auclin, Aurelien de Reynies, Yves Allory, Stephane Oudard
Summary: This study evaluated the safety and efficacy of bevacizumab in combination with chemotherapy for metastatic renal medullary carcinoma and collecting duct carcinoma. The results showed that the addition of bevacizumab did not provide additional benefits and was associated with higher toxicity. Therefore, chemotherapy remains a treatment option for patients with these types of cancers.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
A. Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A. McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro A. A. Castro, Clarice S. Groeneveld, Aurelien de Reynies, Vadim I. Nazarov, Vasily O. Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J. Meeks
Summary: Checkpoint immunotherapy (CPI) has shown efficacy in some advanced-stage bladder cancer patients, but not all. By analyzing tumor and immune microenvironment in pre- and post-treatment tumors, researchers identified genetic and transcriptomic programs associated with response or resistance to CPI. They also discovered that inhibiting the histone demethylase KDM5B enhances immunogenicity in certain subtypes of bladder cancer.
NATURE COMMUNICATIONS
(2023)
Meeting Abstract
Oncology
Jean-Eudes Le Douget, Julien Taieb, Paul Jacob, Frederic Bibeau, Karine Le Malicot, Jean-Francois Emile, Aurelien de Reynies, Mehdi Morel, Simon Jegou, Come Lepage, Pierre Laurent-Puig
Meeting Abstract
Oncology
Benoit Rousseau, Ivan Bieche, Eric Pasmant, Nadim Hamzaoui, Nicolas Leulliot, Lucas Michon, Aurelien de Reynies, Mike Foote, Julien Masliah-Planchon, Magali Svrcek, Romain Cohen, Victor Simmet, Paule Augereau, David Malka, Antoine Hollebecque, Damien Pouessel, Carlos Gomez-Roca, Rosine Guimbaud, Amandine Bruyas, Marielle Guillet, Muriel Duluc, Sophie Cousin, Christelle de la Fourchardiere, Frederic Rolland, Sandrine Hiret, Esma Saada-Bouzid, Olivier Bouche, Thierry Andre, Diane Pannier, Farid El Hajbi, Stephane Oudard, Christophe Tournigand, Jean-Charles Soria, Drew Gerber, Dennis Stephens, Michelle Lamandola-Essel, Steven B. Maron, Bill Diplas, Guillem Argiles, Asha Krishnan, Neil Segal, Andrea Cercek, Nathalie Hoog-Labouret, Frederic Legrand, Clotide Simon, Assia Lamrani-Ghaouti, Luis A. Diaz, Pierre Saintigny, Sylvie Chevret, Aurelien Marabelle
Meeting Abstract
Pathology
Y. Allory, C. S. Groeneveld, V. Harter, C. Krucker, V. Dixon, A. de Reynies, S. Culine, C. Pfister, F. Radvanyi
Letter
Oncology
Yann-Alexandre Vano, Reza Elaidi, Letuan Phan, Maxime Meylan, Wolf Herman Fridman, Catherine Sautes-Fridman, Stephane Oudard
Letter
Oncology
Yann-Alexandre Vano, Reza Elaidi, Letuan Phan, Wolf Herman Fridman, Catherine Sautes-Fridman, Stephane Oudard
Review
Oncology
Margot Revel, Catherine Sautes-Fridman, Wolf-Herman Fridman, Lubka T. Roumenina
Summary: The role of C1q in tumor-associated macrophages is complex and may drive cancer progression, calling for further investigation.